# CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

> **NCT01583686** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (actual)

## Conditions studied

- Cervical Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Mesothelioma
- Lung Cancer

## Interventions

- **DRUG:** Fludarabine
- **BIOLOGICAL:** Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)
- **DRUG:** Cyclophosphamide
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT01583686
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05-04
- **Primary completion:** 2018-12-17
- **Final completion:** 2018-12-17
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Study terminated due to slow/insufficient accrual.
- **Last updated:** 2019-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01583686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01583686, "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01583686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*